Business Wire

TOSHIBA

Share
Toshiba at EuroCIS: Delivering Solutions to Empower Retailers to Go Beyond

At EuroCIS 2024, Toshiba Global Commerce Solutions showcases how retailers can “Create Beyond what’s Possible” to transform retail operations and customer experiences with its innovative solutions portfolio (booth in hall 9 #B42). The international trade fair will take place on February 27-29 in Düsseldorf, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240223284358/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

At EuroCIS 2024, Toshiba Global Commerce Solutions will empower retailers to transform their operations and customer experiences with innovative solutions and services. (Photo: Business Wire)

“Our unified commerce and self-service solutions help retailers create shopping experiences that go beyond consumer expectations,” says Meike Marquardt, Head of Marketing for Europe, Toshiba Global Commerce Solutions. “With Toshiba Global Commerce Solutions as a trusted partner, retailers have the power to adapt effortlessly to the rapidly changing business needs of the industry and to think beyond their limitations.”

During EuroCIS, retailers can experience how Toshiba’s end-to-end solutions backed with the latest innovative technologies empower retailers to transform business with enhanced store insights, operations, and customer experiences. Guests at Toshiba’s booth will encounter self-service solutions that leverage A.I., computer vision, and edge computing technologies that reduce friction and address critical industry challenges like shrink. Toshiba will also feature the Retail Command Center showcasing Connected Services with A.I.-powered analytics that take the store support services model from reactive to proactive. Featured mobile and unified commerce solutions will demonstrate how retailers can evolve with their customers across multiple touchpoints. Solutions in Toshiba’s booth are all part of a composable and modular portfolio that allows retailers to take control of their transformation journey and accelerate change in the way that best suits their business needs.

Self-Service solutions leverage A.I., computer vision and edge computing

  • Toshiba’s Vision Kiosk bypasses barcodes completely by automatically identifying and validating items, typically in convenience, pharmacy and specialty stores. The computer vision self-service kiosk offers the ability to buy items quickly and easily using contactless and biometric payments, powered by PopID.
  • The TCx® SMART Self Checkout offers multiple customisation options including wall-mounted and freestanding solutions, designed to meet changing self-service expectations across retail segments including grocery, specialty and convenience.
  • Toshiba’s Self Checkout System 7 integrates edge computing cameras to minimize shrink while providing consumers enhanced checkout experiences and reduced friction. For produce recognition the TCx EDGEcam leverages A.I. and computer vision integrated with Intel technology to identify produce accurately and fast. Based on retailer data, Toshiba has found that shoppers save as much as five seconds per produce item lookup during checkout. Furthermore, the TCx EDGEcam+ utilizes Qualcomm® System-on-Chip (SoC) technology to enhance loss prevention capabilities, ensuring comprehensive security measures.

A.I.-enabled Connected Services powers operational efficiency in stores

Toshiba’s recently opened Command Center in Brussels is ready to deliver A.I.-enabled Connected Services for retailers. At EuroCIS, retailers will experience the Retail Command Center in real life, showing how A.I.-enabled analytics can identify failure patterns of hardware components and software processes, enabling retailers to drive technology management decisions instantly, changing the store support model from reactive to proactive, minimizing downtime, and lost revenues.

Unified Commerce brings agility to mobile and in-store touchpoints

Modern consumer shopping journeys are constantly evolving, moving from digital to physical, mobile to in-store, and vice-versa. Mobile solutions are a given for shoppers and are essential for in-store staff. Toshiba’s unified commerce makes this easy, leveraging a unified single basket architecture across multiple touchpoints.

Composable and modular software solutions enable retailers to accelerate change

Retailers looking to transform their business and to adopt innovative technologies to meet their consumer expectations can consider solutions to replace a complete platform, as well as composable technologies when wanting to introduce innovative applications step by step. Everything is available in a software-as-a-service (SaaS) model to ease affordability and speed of deployment.

Toshiba will speak on both the Connected Retail & Retail Technology Stages

Toshiba experts will also share their knowledge and expertise on the EuroCIS stages:

February 27 at 12:40 - 1:00 pm on the Connected Retail Stage
How Remote Monitoring can help the retailer to be ahead of the game
Jules Harms, Director Professional Services, Toshiba Global Commerce Solutions

February 28 at 3:00 - 3:20 pm on the Retail Technology Stage
Ground to Cloud – Driving Transformation in Retail
Mike Mooney, Vice President of Solutions, Toshiba Global Commerce Solutions

About Toshiba Global Commerce Solutions:

Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs. Visit commerce.toshiba.com and engage with us on X, formerly known as Twitter, Facebook, LinkedIn, Instagram, and YouTube, to learn more.

Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240223284358/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye